Excellio Labs builds engineered exosome‑based delivery vehicles that are functionalized with tissue‑specific targeting ligands, enabling precise biodistribution of small molecules, proteins, or nucleic acids. Their scalable platform offers low‑immunogenic, biocompatible vesicles that can be customized for a wide range of therapeutic payloads, helping pharma and biotech companies achieve safer and more effective targeted drug delivery.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug delivery methods often lack tissue specificity, leading to off‑target effects, reduced therapeutic efficacy, and safety concerns, especially for treatments targeting complex diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions.
Solution
Excellio Labs develops engineered exosome‑based delivery vehicles that incorporate tissue‑specific targeting ligands (“GPS systems”) to direct therapeutic cargo precisely to the intended organ or cell type. By leveraging the natural biocompatibility and low immunogenicity of extracellular vesicles, the platform enables safe and efficient transport of small molecules, proteins, or nucleic acids. The technology is designed to enhance clinical performance of advanced biologics, expanding the range of treatable targets that were previously inaccessible with conventional delivery systems. Excellio’s platform offers a customizable portfolio of tissue‑specific exosomes, allowing partners to tailor drug delivery to the pharmacological needs of each therapeutic candidate.
Target Audience
Primary customers are pharmaceutical and biotech companies developing biologic therapeutics that require targeted delivery to specific tissues or disease sites.
Features
- Engineered exosome vesicles functionalized with tissue‑specific targeting ligands for precise biodistribution
- Scalable manufacturing process that preserves vesicle integrity and cargo loading efficiency
- Compatibility with a broad range of therapeutic payloads, including RNA, proteins, and small‑molecule drugs
- Low immunogenicity and inherent biocompatibility derived from native extracellular vesicle biology
- Modular platform enabling rapid customization of delivery vehicles for different disease indications